Obecabtagene Autoleucel BLA for Relapsed/Refractory B-ALL Un

The FDA has accepted for review the BLA for obecabtagene autoleucel's use in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Related Keywords

, Cart Cell Therapy , Obecabtagene Autoleucel , B Cell Acute Lymphoblastic Leukemia ,